• Bruker’s third-quarter 2026 non-GAAP diluted EPS climbed 24% year over year to $0.56.
• Non-GAAP operating margin expanded 4 percentage points to 16.3% year over year, while revenue rose to $874 million.
• Scientific Instruments book-to-bill exceeded one for the fifth consecutive quarter.
• Management expects revenue growth acceleration, continued margin expansion and double-digit EPS growth in FY27.
• For FY26, Bruker reaffirmed non-GAAP EPS guidance of $2.10–$2.15.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bruker Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-446176), on November 04, 2026, and is solely responsible for the information contained therein.